Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xenetic Biosciences (XBIO) EPS (Weighted Average and Diluted) (2023 - 2025)

Xenetic Biosciences' EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$0.22 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 67.65% year-over-year to -$0.22; the TTM value through Dec 2025 reached -$1.59, up 38.13%, while the annual FY2025 figure was -$1.58, 38.52% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.22 in Q4 2025 per XBIO's latest filing, up from -$0.33 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.22 in Q4 2025 to a low of -$0.83 in Q2 2024.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$0.58, with a median of -$0.64 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): fell 29.26% in 2024, then surged 67.65% in 2025.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.77 in 2023, then increased by 11.69% to -$0.68 in 2024, then soared by 67.65% to -$0.22 in 2025.
  • Per Business Quant, the three most recent readings for XBIO's EPS (Weighted Average and Diluted) are -$0.22 (Q4 2025), -$0.33 (Q3 2025), and -$0.45 (Q2 2025).